D4264 Bone Replacement Graft — Each Additional Site in Quadrant Template

Bone replacement graft - each additional site in quadrant.

Tooth: #Tooth number(s)
Defect type: Defect type

Defect documentation: Tooth/site, defect type, radiographs, intraoral photo of bony defect
Regenerative materials: Graft/biologic/membrane material and amount
Closure/prognosis: Closure method and expected follow-up

Procedure:
Defect debrided.
Root surface conditioned.
Graft material placed: Graft material/amount
Membrane placed: Membrane used/none
Sutured with: Suture material/size

Site treated in conjunction with D4263.

Complications: None or describe.
Patient tolerance: Tolerance/response.

What documentation is required for D4264?

D4264 lives or dies on per-site documentation. The add-on nature of this code is the audit hook — carriers want to see that each additional site is a distinct, defined defect with its own findings, not a continuation of the D4263 site or a "reload" of graft material into the same defect. Every element below should be visible in the chart for each D4264 unit billed.

• Tooth number or position for each site. List the specific tooth adjacent to each defect (e.g., "D4263 #14 mesial; D4264 #15 distal"). Carriers reading the claim should be able to map each D4264 line to a specific tooth/site.
• Defect classification per site. Use standard terminology: 1-wall, 2-wall, 3-wall infrabony, circumferential, dehiscence, fenestration, furcation Class II/III. The wall count drives prognosis — 3-wall infrabony defects regenerate predictably; 1-wall defects do not. AAP regeneration guidelines tie predictability to defect morphology, and that connection should be visible in the note.
• Defect dimensions per site. Probing depth, clinical attachment level, radiographic depth from CEJ to base of defect, intra-surgical depth from alveolar crest. "5 mm intrabony component on mesial #15" is concrete; "deep defect" is not.
• Pre-op radiographs and intraoral photos of each bony defect. The bone graft documentation list explicitly calls out intraoral images of the bony defect. Many carriers reviewing D4263/D4264 claims request a labeled clinical photo per site — taken at the time of degranulation, before graft placement, with a perio probe in the defect for scale.
• Periodontal diagnosis with AAP staging and grading. Stage III or IV periodontitis is the typical context for regenerative therapy on retained natural teeth; the staging should appear in the chart. Bone grafting on a tooth without documented attachment loss invites recoupment.
• Medical and risk-factor narrative. Smoking status, diabetes (and HbA1c control), bisphosphonate or anti-resorptive therapy, history of head/neck radiation, immunosuppression. Smokers and uncontrolled diabetics have substantially reduced regenerative outcomes; ignoring this in the note is both a clinical and a documentation problem.
• Flap design and access. Sulcular incisions with full-thickness flap reflection are standard; papilla preservation flap technique should be noted by name when used. Document flap extent (teeth involved, vertical releases if any).
• Defect debridement and root surface preparation per site. "Defect debrided" is in the body — strengthen with technique: hand and ultrasonic instrumentation, removal of granulation tissue, exposure of the bony walls.
• Root surface conditioning per site. Citric acid, EDTA, tetracycline paste — agent and dwell time. Many regenerative protocols include conditioning to remove the smear layer; documenting it ties the case to AAP regenerative methodology.
• Graft material and amount per site. Be specific: allograft (DFDBA, FDBA — donor source and lot if available), xenograft (Bio-Oss, OsseoGraft particle size), alloplast (synthetic hydroxyapatite, beta-TCP), autogenous, or composite. Volume in cc or mg. Lot number is helpful for traceability and is required by some accreditation standards.
• Biologic agents per site (if used). Enamel matrix derivative (Emdogain), rhBMP-2, PRF/PRP, growth factors. Each is its own line item and may be reported separately under D4276 or as a "by report" depending on carrier — but the use should be documented even if not separately billed.
• Membrane per site (if used). Resorbable (collagen, PLA/PGA copolymer) or non-resorbable (PTFE, titanium-reinforced PTFE). When a membrane is used as adjunctive coverage of a bone graft, it is generally bundled into D4263/D4264; when membrane placement is the principal regenerative element, the case becomes D4266/D4267 and the bone graft is bundled into the GTR code. Be deliberate about which scenario applies.
• Closure per site. Suture material (chromic gut, vicryl, monocryl, PTFE), size (4-0, 5-0, 6-0), technique (interrupted, sling, mattress), and number of sutures per site if relevant.
• Site treated in conjunction with D4263. This sentence (already in the body) is the link that ties D4264 to its parent first-site claim. It should remain in the note.
• Complications and patient tolerance per site. Bleeding management, flap perforation, intraoperative findings that changed the plan. "None" is acceptable if true; default-normal language across every patient is an audit pattern.
• Post-op instructions and follow-up plan. Chlorhexidine 0.12% rinse, soft diet, avoidance of mechanical disturbance for 4-6 weeks at the surgical site, suture removal at 7-14 days, healing check at 4-6 weeks, re-evaluation of regenerative response at 4-6 months.
• Provider signature and any auxiliary operator initials.

The amnesia test for D4264 is unusually strict: a third party reading the note must be able to (1) identify each individual graft site by tooth, (2) understand why each site needed a separate graft rather than a single confluent graft, and (3) trace each material used to a specific site. Lump-sum language ("multiple defects grafted with allograft") will not survive a serious review.

Why does D4264 get denied?

The most frequent reasons D4264 is denied, downgraded, or recouped:

• D4264 billed without D4263 on the same DOS in the same quadrant. Universal denial. D4264 is an add-on code by design; carriers reject it as incomplete when the first-site D4263 is missing from the claim.
• Per-site documentation is generic or shared with D4263. "Bone graft placed in mesial defects #14, #15" without per-site defect classification, dimensions, photos, or material breakdown reads as one site to a reviewer, not two. The single biggest cause of D4264 downgrades is documentation that doesn't clearly distinguish each additional site from the first.
• Confluent / communicating defect billed as multiple sites. Per CDT, two contiguous teeth with a communicating interproximal osseous defect are one site, not two. Billing D4263 + D4264 for what should have been D4263 alone is a recoupment trigger when the carrier's reviewer reads the radiograph or photo.
• Edentulous ridge graft billed as D4263/D4264. D4263/D4264 require a retained natural tooth. An edentulous ridge augmentation is D7950 or D7953; billing it as a perio bone graft is a categorical denial when the carrier sees no adjacent natural tooth on the radiograph.
• Missing pre-op radiographs and/or intraoral defect photos. Bone graft claims without imaging of the defect are routinely denied for "documentation insufficient." Many carriers explicitly request labeled clinical photos per site for D4263/D4264 review.
• No periodontitis diagnosis / staging. Bone grafting on a tooth without documented attachment loss, deep probing, or radiographic bone loss invites recoupment. AAP staging (Stage III/IV typical) should be in the chart.
• Same-site conflict with D4266/D4267. D4263/D4264 + D4266/D4267 on the same site is generally not paid both. Most carriers pay one based on the principal element of the procedure.
• Frequency violation — same site within lifetime limit. Most carriers limit D4263/D4264 to once per site lifetime. A re-graft at a previously grafted site is commonly denied without a strong narrative documenting failure of the original graft and why retreatment is indicated.
• 24-month lookback after osseous (D4260/D4261) on the same quadrant. Common edit on Delta and Cigna contracts; override requires a narrative tying today's grafting to a defect not addressed by the prior osseous procedure.
• Excessive D4264 units in a single quadrant. >2-3 D4264 units in one quadrant typically triggers a clinical-policy review; some are paid with a strong narrative, others are downgraded to osseous surgery (D4260/D4261) on the assumption the case is broader than discrete sites.
• Membrane separately billed when bundled. When a membrane is used as adjunctive coverage with a bone graft, it is generally bundled into D4263/D4264. Separate billing of D4266 in that scenario is a frequent recoupment trigger.
• Default-template language across patients. Notes where every site reads identically ("3-wall defect, debrided, conditioned, FDBA placed, collagen membrane, sutured") with no patient-specific findings are flagged as fabricated.
• No follow-up plan documented. Regenerative cases need a re-evaluation timeline (typically 4-6 months post-op) to assess regenerative response. Notes without that plan are sometimes downgraded as "no evidence of regenerative intent."

What do practices ask about D4264?

Which templates are related to D4264?